Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | UF-KURE-BCMA CAR-T cells |
| Synonyms | |
| Therapy Description |
UF-KURE-BCMA CAR-T cells are T-cells engineered to express a chimeric antigen receptor (CAR) targeting BCMA, which may inhibit tumor growth (Blood (2023) 142 (Supplement 1): 4848). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| UF-KURE-BCMA CAR-T cells | UF-BCMA CAR-T cells | TNFRSF17 Immune Cell Therapy 27 | UF-KURE-BCMA CAR-T cells are T-cells engineered to express a chimeric antigen receptor (CAR) targeting BCMA, which may inhibit tumor growth (Blood (2023) 142 (Supplement 1): 4848). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06698744 | Phase I | Cyclophosphamide + Fludarabine UF-KURE-BCMA CAR-T cells | UF-KURE-BCMA CAR-T Cells in Patients with Relapsed or Refractory Multiple Myeloma | Not yet recruiting | USA | 0 |